Indications and Usage

Umbralisib is a indicated for the treatment of adult patients with:

• Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen
• Relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.

These indications are approved under accelerated approval based on overall response rate. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Side effects needing medical attention

The most common adverse reactions were increased creatinine, diarrhea, fatigue, nausea, neutropenia (low white blood cell count), transaminase elevation, musculoskeletal pain, anemia, thrombocytopenia (low platelet levels), upper respiratory tract infection, vomiting, abdominal pain, decreased appetite, and rash.

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.